BGM (BGM) | Stock Overview & Key Data
BGM Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $110.00 on January 11, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Financial Highlights
Profitability
Returns and Earnings
Growth
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| BGM BGM | 2.41B Mid-cap | -5.57% | -24.24% | -5.84% | -23.08% | 11.86% | 145.83% | 4.37% | -77.07% |
| Zoetis ZTS | 70.27B Large-cap | 2.18% | -6.53% | -0.27% | -2.53% | -2.11% | -9.02% | -10.56% | 16.11% |
| Haleon Plc - ADR HLN | 47.20B Large-cap | -2.12% | -6.71% | 9.49% | 7.29% | 7.52% | 21.02% | 38.33% | 38.33% |
| Regencell Bioscience RGC | 18.54B Large-cap | 8.16% | -97.12% | -36.29% | 290.47% | 282.37% | 533.33% | -39.50% | 118.95% |
| Elanco Animal Health ELAN | 6.63B Mid-cap | 1.33% | 3.95% | 61.86% | 22.63% | 20.08% | 2.95% | -28.41% | -33.55% |
| Lantheus Holdings LNTH | 5.60B Mid-cap | -3.26% | -4.84% | -17.04% | -18.29% | -10.82% | 1.94% | 18.63% | 457.70% |
Ownership & Short Interest
BGM Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in BGM would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
In the last 52 weeks, BGM reached a high of $17.17 (on June 11, 2025) and a low of $3.89 (on July 8, 2024).
Curious about BGM's size and valuation? Its market capitalization stands at 2.41B. When it comes to valuation, the P/E ratio (trailing twelve months) is 15.00, and the forward P/E (looking ahead) is N/A.
As for dividends, BGM isn't currently offering a significant yield, or that specific data isn't available right now.
When looking at BGM, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Zoetis
ZTS70.27B Healthcare Drug Manufacturers - Specialty & Generic -9.02% -10.56% Haleon Plc - ADR
HLN47.20B Healthcare Drug Manufacturers - Specialty & Generic 21.02% 38.33% Regencell Bioscience
RGC18.54B Healthcare Drug Manufacturers - Specialty & Generic 533.33% -39.50% Elanco Animal Health
ELAN6.63B Healthcare Drug Manufacturers - Specialty & Generic 2.95% -28.41% Lantheus Holdings
LNTH5.60B Healthcare Drug Manufacturers - Specialty & Generic 1.94% 18.63% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
To get a sense of BGM's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -16.52%, the Debt to Equity ratio from the most recent quarter is 0.22, and its Gross Profit Margin stands at N/A.
Looking at BGM's growth, its revenue over the trailing twelve months (TTM) was $30M. Compared to the same quarter last year (YoY), quarterly revenue grew by -56.90%, and quarterly earnings saw a YoY growth of -16.40%.
Wondering who owns BGM stock? Company insiders (like executives and directors) hold about 7.29% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.00%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.